6.3 Hemostasis, Coagulation Cascade & Anticoagulant Actions

6.3 Hemostasis, Coagulation Cascade & Anticoagulant Actions

Hemostasis is the complex, highly regulated physiological process by which the human body stops bleeding following vascular injury, maintains blood in a fluid state within undamaged blood vessels, and eventually dissolves vascular clots after tissue repair is complete. For phlebotomy technicians, understanding hemostatic mechanisms and the chemical actions of blood collection tube additives (anticoagulants and preservatives) is crucial for ensuring valid diagnostic laboratory testing.

The Four Sequential Stages of Hemostasis

When a blood vessel is damaged, hemostasis proceeds immediately through four closely coordinated stages:

+--------------------------------------------------------------------------+
|                        STAGES OF HEMOSTASIS                              |
+--------------------------------------------------------------------------+
|  STAGE 1: Vascular Spasm (Immediate Vasoconstriction)                    |
|       ↓                                                                  |
|  STAGE 2: Primary Hemostasis (Platelet Adhesion, Aggregation & Plug)     |
|       ↓                                                                  |
|  STAGE 3: Secondary Hemostasis (Coagulation Cascade & Fibrin Clot)       |
|       ↓                                                                  |
|  STAGE 4: Fibrinolysis (Plasmin Activation & Clot Dissolution)           |
+--------------------------------------------------------------------------+

Stage 1: Vascular Spasm (Vasoconstriction)

Immediately following blood vessel laceration or trauma, smooth muscle fibers in the vessel wall contract in a neurogenic reflex response. Vascular spasm reduces vessel lumen diameter, instantly slowing blood flow to the injured area and minimizing blood loss. Endothelial cells at the injury site also release chemical paracrines (such as endothelin) that sustain localized vasoconstriction.

Stage 2: Primary Hemostasis (Platelet Plug Formation)

Primary hemostasis involves cellular responses by platelets to form an unstable temporary seal over the endothelial break.

1. Platelet Adhesion: Normally, intact endothelial cells express prostacyclin and nitric oxide to inhibit platelet activation. When endothelium is disrupted, underlying subendothelial collagen is exposed. Circulating von Willebrand factor (vWF) binds to collagen, enabling platelets to adhere securely to the damaged surface via platelet membrane glycoprotein receptors (GPIb).
2. Platelet Activation & Release Reaction: Adhered platelets undergo a dramatic shape change, transforming from smooth discs into spiny spheres with extended pseudopods. They degranulate, releasing chemical mediators including adenosine diphosphate (ADP), thromboxane A2 (TxA2), and serotonin. These substances recruit additional circulating platelets to the site and promote further vasoconstriction.
3. Platelet Aggregation: Recruited platelets cross-link with one another via fibrinogen bridges binding to activated GPIIb/IIIa receptors, forming a primary platelet plug. While this plug halts minor capillary bleeding, it is mechanically weak and must be stabilized by secondary hemostasis.

Stage 3: Secondary Hemostasis (The Coagulation Cascade)

Secondary hemostasis involves a complex series of enzymatic reactions among plasma proteins (coagulation factors I through XIII) culminating in the conversion of soluble fibrinogen into an insoluble, stable fibrin clot. The cascade is traditionally organized into two initiating pathways—the Extrinsic and Intrinsic pathways—which converge into a shared Common Pathway.

    EXTRINSIC PATHWAY                     INTRINSIC PATHWAY
(Tissue Trauma / Factor VII)          (Surface Contact / Factors XII, XI, IX, VIII)
             \                                 /
              \                               /
               v                             v
                   COMMON PATHWAY
             (Factor X Activation -> Prothrombin to Thrombin
              -> Fibrinogen to Fibrin Meshwork)

1. The Extrinsic Pathway (Tissue Factor Pathway)

• Initiation: Triggered by external trauma outside the blood vessel. Damaged tissue releases Tissue Factor (Factor III) or tissue thromboplastin into the bloodstream.
• Cascade: Tissue Factor complexes with calcium ions (Factor IV) and Factor VII to form an enzymatic complex that directly activates Factor X in the common pathway.
• Characteristics: The extrinsic pathway is rapid, generating a response within seconds.
• Laboratory Monitoring: Monitored clinically using the Prothrombin Time (PT) assay, reported as an International Normalized Ratio (INR). PT/INR evaluates oral anticoagulant therapy, specifically warfarin (Coumadin), which inhibits vitamin K-dependent factors (II, VII, IX, X).

2. The Intrinsic Pathway (Contact Activation Pathway)

• Initiation: Triggered by internal vascular injury or contact of circulating blood with negatively charged subendothelial collagen surfaces.
• Cascade: Involves sequential activation of plasma clotting factors: Factor XII (Hageman factor) → Factor XI → Factor IX, which complexes with Factor VIIIa, calcium, and phospholipids to activate Factor X.
• Characteristics: The intrinsic pathway is slower, taking several minutes to complete.
• Laboratory Monitoring: Monitored clinically using the Activated Partial Thromboplastin Time (aPTT) assay. aPTT evaluates intravenous unfractionated heparin therapy.

3. The Common Pathway

• Initiation: Begins when either the extrinsic or intrinsic pathway activates Factor X (to Factor Xa).
• Cascade:
  1. Factor Xa complexes with Factor V, calcium, and phospholipids to form the prothrombinase complex.
  2. Prothrombinase converts Prothrombin (Factor II) into the active enzyme Thrombin (Factor IIa).
  3. Thrombin cleaves soluble Fibrinogen (Factor I) into insoluble Fibrin monomers.
  4. Fibrin monomers polymerize into loose strands, which are then cross-linked by Factor XIIIa (fibrin-stabilizing factor) to form a dense, stable fibrin network that reinforces the primary platelet plug.

Stage 4: Fibrinolysis (Clot Dissolution)

Once tissue repair is complete, the fibrin clot must be removed to re-establish normal vessel patency.

1. Plasminogen Activation: Injured endothelial cells slowly release tissue plasminogen activator (t-PA) into the clot. t-PA converts the inactive plasma proenzyme plasminogen into active plasmin.
2. Fibrin Degradation: Plasmin is a potent proteolytic enzyme that digests fibrin strands, breaking the clot down into soluble fragments called Fibrin Degradation Products (FDPs) and D-dimer.
3. Clinical Significance: Elevated plasma D-dimer levels serve as a critical diagnostic marker for active intravascular thrombosis, such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

---

Mechanisms of Action of Laboratory Anticoagulants and Additives

To preserve blood specimens for diagnostic testing, collection tubes contain specialized chemical additives that target specific steps in the hemostatic or metabolic pathways.

+-----------------------------------------------------------------------------------+
|                        TUBE ADDITIVES & MECHANISMS                                |
+-----------------------------------------------------------------------------------+
|  EDTA (Lavender Top)            → Chelates Calcium (Preserves Cell Morphology)   |
|  Sodium Citrate (Light Blue Top)→ Chelates Calcium (9:1 Ratio for Coagulation)   |
|  Heparin (Green Top)            → Inhibits Thrombin (Activates Antithrombin III)  |
|  Sodium Fluoride (Gray Top)     → Antiglycolytic Agent (Inhibits Enolase)        |
+-----------------------------------------------------------------------------------+

1. Ethylenediaminetetraacetic Acid (EDTA)

• Mechanism: EDTA prevents coagulation by chelating (binding) free ionized calcium (Ca²⁺) in the blood sample, rendering calcium unavailable for the coagulation cascade.
• Tube Stopper Color: Lavender, purple, or pink (blood bank).
• Clinical Applications: EDTA is the additive of choice for Hematology testing (CBC, manual differential, reticulocyte count) because it preserves blood cell morphology and prevents platelet clumping without altering cell volume.

2. Sodium Citrate

• Mechanism: Prevents coagulation by chelating calcium.
• Tube Stopper Color: Light blue.
• Critical Requirement: Must be filled to achieve a strict 9:1 blood-to-anticoagulant ratio (9 parts blood to 1 part sodium citrate).
• Clinical Applications: Sodium citrate is the mandatory additive for Coagulation studies (PT/INR, aPTT, fibrinogen, factor assays) because its calcium-binding action is easily reversed by adding calcium back during laboratory testing.

3. Heparin (Lithium, Sodium, or Ammonium Heparin)

• Mechanism: Heparin prevents clotting by inhibiting thrombin formation. It accelerates the activity of antithrombin III, an endogenous inhibitor that neutralizes thrombin (Factor IIa) and Factor Xa.
• Tube Stopper Color: Green (light green for PST with gel; dark green without gel).
• Clinical Applications: Ideal for Plasma Chemistry testing and STAT electrolytes, as plasma can be centrifuged immediately without waiting for a clot to form.

4. Sodium Fluoride and Potassium Oxalate

• Mechanism: Potassium oxalate acts as an anticoagulant by binding and precipitating calcium as calcium oxalate. Sodium fluoride acts as an antiglycolytic agent, inhibiting the metabolic enzyme enolase to prevent red blood cells from consuming glucose (glycolysis).
• Tube Stopper Color: Gray.
• Clinical Applications: Used for Glucose tolerance testing, blood alcohol levels, and lactate determinations.

---

Clinical Scenarios, Underfill Traps & Order of Draw Traps

• Underfilled Light Blue Tube Trap: If a light blue top tube is underfilled (e.g., achieving a 5:1 ratio instead of 9:1), the relative concentration of liquid sodium citrate is excessively high. When the lab analyzer adds standard calcium reagent, the excess citrate chelates the added calcium, resulting in falsely prolonged PT and aPTT times. Underfilled coagulation tubes must be rejected.
• Additive Carryover & Order of Draw: Drawing an EDTA tube before a sodium citrate tube causes EDTA carryover into the citrate tube. EDTA's high binding affinity for calcium and potassium will severely distort coagulation tests and falsely elevate potassium levels (EDTA contains K₂ or K₃). Following the CLSI Order of Draw (Yellow/Blood Cultures → Light Blue → Red/SST → Green → Lavender → Gray) prevents cross-contamination.